An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia

European Journal of Anaesthesiology

Volumn 24, Issue 11, 2007, Pages 912-919

  Iohom, Gabriella ^a,c   Ni Chonghaile, M ^a   O'Brien, J K ^b   Cunningham, A J ^a   Fitzgerald, D F ^b   Shields, D C ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c University College Cork and INFANT Centre   (Ireland)

Author keywords

Anaesthesia intravenous; CYP2B6; Gabre protein human; Genotype; Propofol

Indexed keywords

CYTOCHROME P450 2B6; GENOMIC DNA; MESSENGER RNA; NITROUS OXIDE; PROPOFOL; REMIFENTANIL;

ADULT; AGED; ANESTHESIA INDUCTION; ANESTHETIC RECOVERY; ARTICLE; BISPECTRAL INDEX; CHROMOSOME XQ; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GABRE GENE; GENE MAPPING; GENERAL ANESTHESIA; GENOTYPE; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFUSION PUMP; INTRAVENOUS ANESTHESIA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; X CHROMOSOME LINKAGE;

ADOLESCENT; ADULT; AGED; ALLELES; ANESTHESIA RECOVERY PERIOD; ANESTHESIA, INTRAVENOUS; ANESTHETICS, INTRAVENOUS; ARYL HYDROCARBON HYDROXYLASES; CHROMOSOMES, HUMAN, X; DNA; ELECTROENCEPHALOGRAPHY; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROPOFOL; RECEPTORS, GABA-A;

EID: 35148901576     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1017/S0265021507000476     Document Type: Article

References (25)

1. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24: 449-459.
2. Ingelman-Sundberg M. Functional consequences of polymorphism of xenobiotic metabolizing enzymes. Toxicol Lett 1998; 102-103: 155-160.
3. Watson KR, Shah MV. Clinical comparison of 'single agent' anaesthesia with sevoflurane versus target controlled infusion of propofol. Br J Anaesth 2000; 85: 541-546.
4. Patten D, Foxon GR, Martin KF, Halliwell RF. An electrophysiological study of the effects of propofol on native neuronal ligand-gated ion channels. Clin Exp Pharmacol Physiol 2001; 28: 451-458.
5. Krasowki MD, Jenkins A, Flood P, Kung AY, Hopfinger A, Harrison NL. General anaesthetic potencies of a series of propofol analogs correlate with potency for potentiation of gamma-aminobutyric acid (GABA) current at the GABA(A) receptor but not with lipid solubility. J Pharmacol Exp Ther 2001; 297: 338-351.
6. Buggy DJ, Nicol B, Rowbotham DJ, Lambert DG. Effects of intravenous anaesthetic agents on glutamate release: a role for GABAA receptor-mediated inhibition. Anaesthesiology 2000; 92: 1067-1073.
7. Davies PA, Hanna MC, Hales TG, Kirkness EF. Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit. Nature 1997; 385: 820-823.
8. Wilke K, Gaul R, Klauck SM, Poustka A. A gene in human chromosome band Xq28 (GABRE) defines a putative new subunit class of the GABA(A) neurotransmitter receptor. Genomics 1997; 45: 1-10.
9. Hachenberg T. Perioperative management with short-acting intravenous anaesthetics. Anaesthesiol Reanim 2000; 25: 144-150.
10. Gan TJ, Glass PS, Sigl J et al. Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men. Anesthesiology 1999; 90: 1283-1287.
11. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001; 94: 110-119.
12. Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
13. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003; 45: 122-132.
14. Irizarry K, Kustanovich V, Li C et al. Genome-wide analysis of single nucleotide polymorphisms in human expressed sequences. Nat Genet 2000; 26: 233-236.
15. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434. Epub 2001 Dec 27.
16. Mander AP. Haplotype analysis in population-based association studies. Stata J 2001; 1: 58-75.
17. Sigl JC, Chamoun NG. An introduction to bispectral analysis for the electroencephalogram. J Clin Monit 1994; 10: 392-404.
18. Glass PSA, Bloom M, Kearse L, Rosow C, Sebel P, Manberg P. Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane and alfentanil in healthy volunteers. Anesthesiology 1997; 86: 836-847.
19. Johansen JW, Sebel PS. Development and clinical application of electroencephalographic bispectrum monitoring. Anesthesiology 2000; 93: 1336-1344.
20. Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. Pharmacology 1997; 281: 226-232.
21. Smith BE. Pharmacokinetics without calculus - an introduction. Int Anesthesiol Clin 1995; 33: 11-28.
22. Morgan DJ, Campbell GA, Crankshaw DP. Pharmacokinetics of propofol when given by intravenous infusion. Br J Clin Pharmacol 1990; 30: 144-148.
23. Hesse LM, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14: 225-238.
24. Guitton J, Buronfosse T, Desage M et al. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth 1998; 80: 788-795.
25. Hoymork SC, Raeder J, Grimsmo B, Steen PA. Bispectral index, predicted and measured drug levels of target-controlled infusions of remifentanil and propofol during laparoscopic cholecystectomy and emergence. Acta Anaesthesiol Scand 2000; 44: 1138-1144.